Martin Shkreli’s drug company is losing money

The former Turing Pharmaceuticals, now on its third corporate identity, is not in good health.

As STAT’s Adam Feuerstein reports, revenue is on the decline at the company, which is now called Phoenixus. Although the company does not break out revenue by product in its financial statements, it relies heavily on Daraprim, whose price famously leapt 5,000% after Martin Shkreli acquired it.

Employees also say management has reneged on promised bonuses.

Read more.